Parallax Volatility Advisers, L.P. Avadel Pharmaceuticals PLC Transaction History

Parallax Volatility Advisers, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$5.02 - $10.0 $55,511 - $110,580	11,058 New	11,058 $79,000
Q1 2022 May 16, 2022	SELL	$5.46 - $8.29 $377,815 - $573,643	-69,197 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.34 - $11.18 $380,116 - $578,978	51,787 Added 297.46%	69,197 $559,000
Q3 2021 Nov 15, 2021	BUY	$6.49 - $9.91 $112,990 - $172,533	17,410 New	17,410 $171,000
Q2 2021 Aug 16, 2021	SELL	$6.73 - $9.05 $78,660 - $105,776	-11,688 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$6.61 - $10.07 $77,257 - $117,698	11,688 New	11,688 $106,000
Q4 2018 Feb 14, 2019	SELL	$1.74 - $4.66 $4,144 - $11,100	-2,382 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$4.08 - $7.14 $62,118 - $108,706	-15,225 Reduced 86.47%	2,382 $10,000
Q2 2018 Aug 14, 2018	BUY	$5.89 - $7.78 $16,821 - $22,219	2,856 Added 19.36%	17,607 $108,000
Q1 2018 May 15, 2018	BUY	$6.76 - $11.7 $99,716 - $172,586	14,751 New	14,751 $108,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.